@angiex.com
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
Icon
JPEG
About
Description
Angiex is a pioneering brand dedicated to revolutionizing cancer treatment. They are developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that specifically target the hallmarks of cancer lethality. Angiex's groundbreaking ND-ADCs are designed to exploit novel biology, particularly an intracellular transporter called TM4SF1, which is highly expressed in the tumor micro-environment.
By delivering therapeutic payloads directly to tumor cells and tumor vascular endothelium, Angiex aims to achieve exceptional efficacy with minimal impact on healthy tissue. The potential of Angiex's ND-ADCs lies in their ability to enable regression of angiogenic tumor vasculature, kill invasive and metastatic tumor cells, and activate the immune system. Their lead product, AGX101, is on its way to clinical trials, with a pipeline of additional ND-ADCs in development.
Driven by a passionate and experienced leadership team, Angiex is motivated to save lives through innovative science. They value curiosity, creativity, collaboration, and inclusivity. Based in Cambridge, MA, they are actively seeking partnerships to further their mission.
Reach out to Angiex today and join their pursuit of a world without cancer
Company Type
Privately Held
Company Size
11-50
Year Founded
2015
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online